Literature DB >> 8263007

Radioimmunotherapy: no news from the newcomer.

A M Mello, E K Pauwels, F J Cleton.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 8263007     DOI： 10.1007/bf01202189

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  95 in total

1.  Plasmapheresis in radioimmunotherapy of micrometastases: a mathematical modeling and dosimetrical analysis.

Authors:  G Sgouros
Journal:  J Nucl Med       Date:  1992-12       Impact factor: 10.057

2.  The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies.

Authors:  D PRESSMAN; L KORNGOLD
Journal:  Cancer       Date:  1953-05       Impact factor: 6.860

Review 3.  Monoclonal antibody-based therapies of leukemia and lymphoma.

Authors:  M L Grossbard; O W Press; F R Appelbaum; I D Bernstein; L M Nadler
Journal:  Blood       Date:  1992-08-15       Impact factor: 22.113

4.  The zone of activity of antibodies as determined by the use of radioactive tracers; the zone of activity of nephritoxic antikidney serum.

Authors:  D PRESSMAN; G KEIGHLEY
Journal:  J Immunol       Date:  1948-06       Impact factor: 5.422

5.  Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells.

Authors:  F Geissler; S K Anderson; P Venkatesan; O Press
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

6.  Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer.

Authors:  D S Wilbur; S W Hadley; M D Hylarides; P G Abrams; P A Beaumier; A C Morgan; J M Reno; A R Fritzberg
Journal:  J Nucl Med       Date:  1989-02       Impact factor: 10.057

7.  Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125.

Authors:  M G Muto; N J Finkler; A I Kassis; A E Howes; L L Anderson; C C Lau; V R Zurawski; K Weadock; S S Tumeh; P Lavin
Journal:  Gynecol Oncol       Date:  1992-06       Impact factor: 5.482

8.  Improving the tumor retention of radioiodinated antibody: aryl carbohydrate adducts.

Authors:  S A Ali; S D Warren; K Y Richter; C C Badger; J F Eary; O W Press; K A Krohn; I D Bernstein; W B Nelp
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

9.  A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.

Authors:  D A Scheinberg; D J Straus; S D Yeh; C Divgi; P Garin-Chesa; M Graham; K Pentlow; D Coit; H F Oettgen; L J Old
Journal:  J Clin Oncol       Date:  1990-05       Impact factor: 44.544

10.  Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity.

Authors:  J Azuma; T Kurimoto; S Tsuji; N Mochizuki; S Fujinaga; Y Matsumoto; Y Masuho
Journal:  J Immunother (1991)       Date:  1991-08
View more
  1 in total

1.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Authors:  D B Axworthy; J M Reno; M D Hylarides; R W Mallett; L J Theodore; L M Gustavson; F Su; L J Hobson; P L Beaumier; A R Fritzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.